CAR T for NHL Market

Chimeric antigen receptor (CAR) T-cell therapy consists of genetic alteration of patients' autologous T-cells to express a CAR, particularly for a tumor antigen, followed by ex vivo cell expansion and re-infusion back to the patient. CAR T-cells are the fusion proteins of a particular single-chain fragment variable from a particular monoclonal antibody and one or more T-cell receptor intracellular signaling domains.

T-cell genetic modification may occur via viral-based gene transfer methods or non-viral methods, such as DNA-based transposons, CRISPR/Cas9 technology, and zinc finger nuclease (ZFN), transcription activator-like effector nuclease (TALEN), or direct transfer of in vitro transcribed-mRNA by electroporation. Non-Hodgkin's Lymphoma (NHL) is a type of blood cancer that consists of a heterogeneous group of proliferative malignancies that emerge in the B cells, T cells, or natural killer (NK) cells within the lymphoid tissue, like the lymph nodes, bone marrow, thymus, and spleen.

B-cell lymphomas comprise around 85% of all NHL cases diagnosed in the United States and are blood cancers that arise in the B-cells. 


Diffuse large B-cell Lymphoma (DLBCL) is the most common type of NHL, accounting for about To date22% of newly diagnosed cases of B-cell NHL in the United States.  


CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market

Market Size of CAR T-Cell Therapy for Non-Hodgkin's Lymphoma in the 6MM is anticipated to be USD 2796.2 Million in 2030.

Market Drivers 

  • Advancements in technology
  • Increased collaborations and acquisitions
  • Competition among biotech and pharma giants

Market Barriers 

  • Adverse events and toxicity concerns
  • Regulatory challenges
  • High cost and low accessibility


The US Food and Drug Administration, to date, has approved two forms of CAR T cell therapy for patients with Non-Hodgkin Lymphoma. The City of Hope is one of the only institutions in the United States to offer both FDA-approved commercial products, Yescarta (axicabtagene ciloleucel) and Kymriah (tisagenlecleucel). 

Marketed CAR T-Cell Therapies for Non-Hodgkin's Lymphoma 

  • Kymriah by Novartis
  • YESCARTA by Kite Pharma (Gilead Sciences)

Emerging CAR T-Cell Therapies for Non-Hodgkin's Lymphoma

  • KTE-X19 by Gilead Sciences
  • JCAR017 by Celgene Corporation (a BMS company)